PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib ; volume:12 ; number:1 ; day:21 ; month:7 ; year:2022 ; pages:1-19 ; date:12.2022
Scientific reports ; 12, Heft 1 (21.7.2022), 1-19, 12.2022
- Urheber
-
Ding, Xia
Zhu, Zhou
Lapek, John
McMillan, Elizabeth A.
Zhang, Alexander
Chung, Chi-Yeh
Dubbury, Sara
Lapira, Jennifer
Firdaus, Sarah
Kang, Xiaolin
Gao, Jingjin
Oyer, Jon
Chionis, John
Rollins, Robert A.
Li, Lianjie
Niessen, Sherry
Bagrodia, Shubha
Zhang, Lianglin
VanArsdale, Todd
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-022-16623-3
- URN
-
urn:nbn:de:101:1-2022100100580446903467
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ding, Xia
- Zhu, Zhou
- Lapek, John
- McMillan, Elizabeth A.
- Zhang, Alexander
- Chung, Chi-Yeh
- Dubbury, Sara
- Lapira, Jennifer
- Firdaus, Sarah
- Kang, Xiaolin
- Gao, Jingjin
- Oyer, Jon
- Chionis, John
- Rollins, Robert A.
- Li, Lianjie
- Niessen, Sherry
- Bagrodia, Shubha
- Zhang, Lianglin
- VanArsdale, Todd
- SpringerLink (Online service)
Ähnliche Objekte (12)
PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
PARP inhibitors
Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
In silico characterisation of AtPARP1 and virtual screening for AtPARP inhibitors to increase resistance to abiotic stress
PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer
Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts
Advances and perspectives of PARP inhibitors
PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy
The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity
PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
PARP inhibitors
Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
In silico characterisation of AtPARP1 and virtual screening for AtPARP inhibitors to increase resistance to abiotic stress
PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer
Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts
Advances and perspectives of PARP inhibitors
PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy
The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity
PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
PARP inhibitors
Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
In silico characterisation of AtPARP1 and virtual screening for AtPARP inhibitors to increase resistance to abiotic stress
PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer
Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts
Advances and perspectives of PARP inhibitors
PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy